#EASD26: Lilly’s amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetes - Endpoints News

#EASD26: Lilly’s amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetes – Endpoints News

October 4, 2026

#EASD26: Lilly’s amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetes Endpoints NewsWhy Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s CNBCLilly’s retatrutide: peer-reviewed Phase 3 shows up to 25% weight loss plus knee-pain and sleep-apnoea gains DealroomPeople with Type 2 diabetes lost up to 60 pounds on Lilly’s latest weight loss drug NBC News‘Godzilla’ of weight-loss drugs could provide other important health benefits The Guardian